Erik Berntorp
1 – 100 of 329
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
- 2023
-
Mark
Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children : Systematic and targeted literature reviews
(
- Contribution to journal › Scientific review
-
Mark
A need to increase von Willebrand disease awareness : vwdtest.com – A global initiative to help address this gap
(
- Contribution to journal › Scientific review
-
Mark
Immune tolerance induction in development
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
(
- Contribution to journal › Scientific review
-
Mark
Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
(
- Contribution to journal › Article
-
Mark
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia : A review of the literature
(
- Contribution to journal › Scientific review
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
- 2022
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
-
Mark
Sixth Åland Island Conference on von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81–8973
(
- Contribution to journal › Article
-
Mark
Alternative payment models for durable and potentially curative therapies : The case of gene therapy for haemophilia A
(
- Contribution to journal › Article
-
Mark
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
(
- Contribution to journal › Article
- 2021
-
Mark
Optimising prophylaxis in haemophilia A : The ups and downs of treatment
(
- Contribution to journal › Scientific review
-
Mark
The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
(
- Contribution to journal › Article
-
Mark
Haemophilia
(
- Contribution to journal › Scientific review
-
Mark
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa
(
- Contribution to journal › Article
-
Mark
Treatment outcomes in persons with severe haemophilia B in the Nordic region : The B-NORD study
(
- Contribution to journal › Article
-
Mark
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study
(
- Contribution to journal › Article
-
Mark
Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation
(
- Contribution to journal › Article
-
Mark
Translating the success of prophylaxis in haemophilia to von Willebrand disease
(
- Contribution to journal › Scientific review
-
Mark
In response to WFH guidelines for the management of haemophilia, 3rd edition : Is there a difference between extended-half-life FVIII products or not?
(
- Contribution to journal › Letter
-
Mark
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
(
- Contribution to journal › Article
- 2020
-
Mark
Achieving the unimaginable : Health equity in haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach
(
- Contribution to journal › Article
-
Mark
Direct comparison of two extended half-life PEGylated recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
(
- Contribution to journal › Article
-
Mark
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study
(
- Contribution to journal › Article
-
Mark
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease : Results from 3WINTERS-IPS, an international and collaborative cross-sectional study
(
- Contribution to journal › Article
- 2019
-
Mark
Evaluation of a standardized protocol for thrombin generation using the calibrated automated thrombogram : A Nordic study
(
- Contribution to journal › Article
-
Mark
Factor VIII : Long-established role in haemophilia A and emerging evidence beyond haemostasis
(
- Contribution to journal › Scientific review
-
Mark
Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia : A comparison between intermediate- and high-dose prophylaxis
(
- Contribution to journal › Article
-
Mark
Coagulation factor VIII is vital for increasing global coagulation after physical exercise
(
- Contribution to journal › Article
-
Mark
Moderate haemophilia in focus
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Cardiovascular disease-related hospitalization and mortality among persons with von Willebrand disease : A nationwide register study in Sweden
(
- Contribution to journal › Article
-
Mark
ROTEM and vitro reversal of warfarin with APCC
(
- Contribution to journal › Article
-
Mark
Hypertension and cardiovascular diseases in Swedish persons with haemophilia — A longitudinal registry study
(
- Contribution to journal › Article
-
Mark
A personalized approach to the management of VWD
(
- Contribution to journal › Article
-
Mark
Joint comorbidities among Swedish carriers of haemophilia : A register-based cohort study over 22 years
(
- Contribution to journal › Article
-
Mark
Direct comparison of two extended-half-life recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Evolution of replacement therapy for von Willebrand disease : From plasma fraction to recombinant von Willebrand factor
(
- Contribution to journal › Scientific review
-
Mark
Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders : An EHA Consensus Report
(
- Contribution to journal › Article
- 2018
-
Mark
Immune tolerance induction : What have we learned over time?
(
- Contribution to journal › Scientific review
-
Mark
Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis : Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network
(
- Contribution to journal › Article
-
Mark
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII
(
- Contribution to journal › Article
-
Mark
The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment
(
- Contribution to journal › Article
-
Mark
Replacement therapy during surgery in von Willebrand disease needs personalization
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Evaluation of prophylactic therapy in haemophilia with global coagulation tests
(
- Contribution to journal › Letter
-
Mark
Fifth Åland Island conference on von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Defining extended half-life rFVIII-A critical review of the evidence
(
- Contribution to journal › Article
- 2017
-
Mark
Low agreement between fresh and frozen-thawed platelet-rich plasma in the calibrated automated thrombogram assay
(
- Contribution to journal › Article
-
Mark
The importance of genetic factors for the development of arthropathy : A longitudinal study of children and adolescents with haemophilia A
(
- Contribution to journal › Article
-
Mark
The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany
(
- Contribution to journal › Article
-
Mark
European retrospective study of real-life haemophilia treatment
(
- Contribution to journal › Article
-
Mark
Von Willebrand disease - the 'Dos' and 'Don'ts' in surgery
(
- Contribution to journal › Article
-
Mark
Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics
(
- Contribution to journal › Article
-
Mark
Thrombin generation assays (TGAs)
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Correlation to FVIII : C in two thrombin generation tests: TGA-CAT and INNOVANCE ETP
(
- Contribution to journal › Article
-
Mark
Preference-based valuation of treatment attributes in haemophilia A using web survey
(
- Contribution to journal › Article
-
Mark
Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy : The Malmö experience
(
- Contribution to journal › Article
-
Mark
The association between health utility and joint status among people with severe haemophilia A : findings from the KAPPA register
(
- Contribution to journal › Article
-
Mark
Comparative burden of arthropathy in mild haemophilia : a register-based study in Sweden
(
- Contribution to journal › Article
-
Mark
If you know you will also see : Population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Plasma-derived versus recombinant factor concentrates in PUPs : A never ending debate?
(
- Contribution to journal › Article
- 2016
-
Mark
ROTEM monitoring of activated and non-activated prothrombin complex concentrate correction of dilutional coagulopathy.
(
- Contribution to journal › Article
-
Mark
Population Pharmacokinetics of Plasma-Derived Factor IX: Procedures for Dose Individualization.
(
- Contribution to journal › Article
-
Mark
Haemophilia treatment in 2030
(
- Contribution to journal › Article
-
Mark
Phenotype and genotype comparisons in carriers of haemophilia A
(
- Contribution to journal › Article
-
Mark
Liposuction in Dercum’s disease
2016) p.657-660(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Malignancies in Swedish persons with haemophilia : a longitudinal registry study
(
- Contribution to journal › Article
-
Mark
Patients Referred for Bleeding Symptoms of Unknown Cause : Does Evaluation of Thrombin Generation Contribute to Diagnosis?
(
- Contribution to journal › Article
-
Mark
Hypertension, haematuria and renal functioning in haemophilia - a cross-sectional study in Europe
(
- Contribution to journal › Article
-
Mark
Registry-based outcome assessment in haemophilia : a scoping study to explore the available evidence
(
- Contribution to journal › Article
-
Mark
The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands
(
- Contribution to journal › Article
-
Mark
Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products
(
- Contribution to journal › Article
-
Mark
The effect of Nordic Walking on joint status, quality of life, physical ability, exercise capacity and pain in adult persons with haemophilia
(
- Contribution to journal › Article
-
Mark
Future of haemophilia outcome assessment : Registries are key to optimized treatment
(
- Contribution to journal › Article
-
Mark
Epidemiological aspects of inhibitor development in hemophilia and strategies of management
(
- Contribution to journal › Scientific review
-
Mark
Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
2016) In Haemophilia(
- Contribution to journal › Article
-
Mark
Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
(
- Contribution to journal › Article
- 2015
-
Mark
The ageing patient with haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Effects of recombinant human prothrombin on thrombin generation in plasma from patients with haemophilia A and B.
(
- Contribution to journal › Article
-
Mark
Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A.
(
- Contribution to journal › Letter
-
Mark
Prophylaxis Escalation in Severe von Willebrand Disease: A Prospective Study from the von Willebrand Disease Prophylaxis Network.
(
- Contribution to journal › Article
-
Mark
Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.
(
- Contribution to journal › Article
-
Mark
Evaluation of Algorithms for the Treatment of Problem Bleeding Episodes in Patients With Hemophilia Having Inhibitors.
(
- Contribution to journal › Article
-
Mark
Association between bleeding tendency and health-related quality of life in carriers of moderate and severe haemophilia.
(
- Contribution to journal › Article
-
Mark
Inhibitors in haemophilia: what have we learned from registries? A systematic review.
(
- Contribution to journal › Scientific review
-
Mark
The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Thrombin stimulates insulin secretion via protease-activated receptor-3.
(
- Contribution to journal › Article
-
Mark
Targeting Factor Replacement Therapy in Severe Hemophilia: Which Level Is Important?
(
- Contribution to journal › Article
-
Mark
Introduction.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Comorbidities and inhibitors in adult patients with haemophilia: issues, costs and management strategies.
(
- Contribution to journal › Scientific review
-
Mark
Acute effects of exercise on specific and global coagulation parameters in severe haemophilia A.
(
- Contribution to journal › Letter
-
Mark
Interaction between VWF and FVIII in treating VWD
(
- Contribution to journal › Article
-
Mark
Tranexamic acid - an old drug still going strong and making a revival.
(
- Contribution to journal › Scientific review
-
Mark
Bleeding phenotype in carriers of haemophilia A does not correlate with thrombin generation
(
- Contribution to journal › Letter
- 2014
-
Mark
Introduction.
(
- Contribution to journal › Article
-
Mark
Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.
(
- Contribution to journal › Scientific review